

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (previously presented): A pharmaceutical composition comprising (a) a compound selected from aripiprazole or a metabolite of aripiprazole wherein the metabolite of aripiprazole is selected from the group consisting of dehydroaripiprazole, DM-1458, DM-1451, DM-1452, DM-1454 and DCPD in combination with (b) at least one serotonin reuptake inhibitor selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram and salts thereof.

2-36. (canceled).

37. (currently amended): A pharmaceutical composition comprising aripiprazole in combination with at least one serotonin reuptake inhibitor selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, ~~setraline~~sertraline and salts thereof.

38. (previously presented): The pharmaceutical composition comprising aripiprazole in combination with at least one serotonin reuptake inhibitor selected from escitalopram and a salt thereof.

39. (previously presented): The composition of claim 37 wherein the at least one serotonin reuptake inhibitor is citalopram.

40. (previously presented): The composition of any one of claims 1, 37, 38 and 39, wherein aripiprazole is anhydrous aripiprazole crystals B.

41. (previously presented): The composition of any one of claims 1, 37, 38 and 39, further comprising at least one pharmaceutically acceptable carrier.

42. (canceled).

43. (currently amended): The composition of any one of claims 1, 37, 38 and 39 being useful for the treatment of claim 42 wherein the mood disorder is depression or major depressive disorder.

44. (currently amended): The composition of any one of claims 1, 37, 38 and 39 being useful for the treatment of claim 42 wherein the mood disorder is major depressive disorder, all mood disorders, schizoaffective disorder or dementia with depressive symptoms.

45. (previously presented): The composition of any one of claims 1, 37, 38 and 39 being useful for treatment of major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's

disease with depressive symptom, senile dementia, mood disorder associated with cerebral blood vessels and mood disorder following head injury.

46. (previously presented): A pharmaceutical composition comprising at least one metabolite of aripiprazole selected from the group consisting of dehydroaripiprazole, DM-1458, DM-1451, DM-1452, DM-1454 and DCPD in combination with at least one serotonin reuptake inhibitor selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram and salts thereof.

47. (previously presented): The composition of claim 46 wherein the at least one serotonin reuptake inhibitor is citalopram.

48. (previously presented): The composition of claim 46 wherein the at least one serotonin reuptake inhibitor is escitalopram.

49. (previously presented): The composition of any one of claims 46 to 48, further comprising at least one pharmaceutically acceptable carrier.

50. (canceled).

51. (currently amended): The composition of ~~claim 50 wherein the mood disorder is any~~
one of claims 46 to 48 being useful for the treatment of depression or major depressive disorder.

52. (currently amended): The composition of ~~claim 50 wherein the mood disorder is any one of claims 46 to 48 being useful for the treatment of major depressive disorder, all mood disorders, schizoaffective disorder or dementia with depressive symptoms.~~

53. (previously presented): The composition of any one of claims 46 to 48 being useful for treatment of major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptom, senile dementia, mood disorder associated with cerebral blood vessels and mood disorder following head injury.

54. (currently amended): A method of treating a mood disorders disorder selected from the group consisting of depression of major depressive disorder, dementia with depressive symptoms, major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptoms, senile dementia, mood disorders associated with cerebral blood vessels and mood disorders following head injury in a patient comprising administration of an effective amount of a pharmaceutical composition which comprise(s) a compound selected from aripiprazole or metabolite of aripiprazole wherein the metabolite of aripiprazole is selected from the group consisting of dehydroaripiprazole, DM-1458, DM-1451, DM-1452, DM-1454 and DCPD in combination with (b) at least one serotonin reuptake inhibitor selected from the group

consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram and salts thereof.

55. (currently amended): A method of treating a mood disorders-disorder selected from the group consisting of depression of major depressive disorder, dementia with depressive symptoms, major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptoms, senile dementia, mood disorders associated with cerebral blood vessels and mood disorders following head injury in a patient comprising administration of an effective amount of a pharmaceutical composition comprising aripiprazole in combination with at least one serotonin reuptake inhibitor selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline and salts thereof.

56. (currently amended): The method of a treating mood disorders-disorder selected from the group consisting of depression of major depressive disorder, dementia with depressive symptoms, major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptoms, senile dementia, mood disorders associated with cerebral blood vessels and mood disorders following head injury in a patient comprising administration of an

effective amount of a pharmaceutical composition comprising aripiprazole in combination with at least one serotonin reuptake inhibitor selected from escitalopram and salt thereof.

57. (previously presented): The method of claim 55 wherein at least one serotonin reuptake inhibitor is citalopram.

58. (previously presented): The method of any one of claims 54 to 57 wherein aripiprazole is anhydrous aripiprazole crystals B.

59. (previously presented): The method of any one claims 54 to 57, wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable carrier.

60. (currently amended): The method of any one claims 54 to 57, ~~wherein the mood disorder is~~being useful for the treatment of depression of major depressive disorder.

61. (currently amended): The method of any one of claims 54 to 57, ~~wherein the mood disorder is~~being useful for the treatment of major depressive disorder, ~~all mood disorders, schizoaffective disorder or dementia with depressive symptoms.~~

62. (currently amended): The method of any one of claims 54 to 57, ~~wherein the mood disorders are~~being useful for the treatment of major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder ~~with~~with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive

symptoms, Parkinson's disease with depressive symptom, senile dementia, mood disorder associated with cerebral blood vessels and mood disorder following head injury.

63. (currently amended): A method of treating a mood disorder selected from the group consisting of depression of major depressive disorder, dementia with depressive symptoms, major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptoms, senile dementia, mood disorders associated with cerebral blood vessels and mood disorders following head injury in a patient comprising administration of an effective amount of pharmaceutical composition comprising at least one metabolite of aripiprazole selected from the group consisting of dehydroaripiprazole, DM-1458, DM-1451, DM-1452, DM-1454 and DCPD in combination with at least one serotonin reuptake inhibitor selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram and salts thereof.

64. (previously presented): A method of claim 63 wherein the at least one serotonin reuptake inhibitor is citalopram.

65. (previously presented): The method of claim 63 wherein the at least one serotonin reuptake inhibitor is escitalopram.

66. (previously presented): The method of any one of claims 63 to 65 wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable carrier.

67. (currently amended): The method of any one of claims 63 to 65 ~~wherein the mood disorder is~~being useful for the treatment of depression of major depressive disorder.

68. (currently amended): The method of any one of claims 63 to 65 ~~wherein the mood disorder is~~being useful for the treatment of major depressive disorder, ~~all mood disorders, schizoaffective disorder~~ or dementia with depressive symptoms.

69. (currently amended): The method of any one of claims 63 to 65 ~~wherein the mood disorders are~~being useful for the treatment of major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptom, senile dementia, mood disorder associated with cerebral blood vessels and mood disorder following head injury.